Found 10 clinical trials
Switching Regimen in Treating Cirrhotic HCV GT1b Subjects
This is a prospective, randomized study to evaluate the efficacy and safety of switching treatment from Peg-interferon and Ribavirin to direct-acting antiviral agents in Chinese with CHC
- 15 views
- 09 Sep, 2021
- 2 locations
Liver Test Study of Using JKB-122 in HCV-Positive Patients
been nonresponsive to, intolerable to, or relapsed from prior interferon-based therapies (pegylated or standard) either alone or in combination with ribavirin or other anti-HCV therapies
- 32 views
- 07 Nov, 2020
- 5 locations
MANS-NRIZ Trial for COVID-19 Treatment : Extension Study
This search will focus on patients with COVID 19 infection this study is a prospective cohort study based on the analysis of response in comparative panel between two arm Nitazoxanide, Ribavirin
- 0 views
- 21 Jul, 2021
- 1 location
Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir (STRIVE-4)
This study aims to evaluate the efficacy, safety and feasibility of four weeks of sofosbuvir plus glecaprevir-pibrentasvir, followed by immediate retreatment of virological relapse with glecepravir-pibrentasvir for 12 weeks, in treatment-naïve participants with chronic HCV infection and early liver disease (F0-F2).
- 0 views
- 27 Apr, 2022
- 3 locations
Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection (PURGE-C)
The purpose of this study is to assess the efficacy of a fixed dose combination (FDC) of glecaprevir/pibrentasvir (G/P) given for 4 weeks in acute hepatitis C (HCV)-infected participants, with or without HIV-1 coinfection.
- 16 views
- 24 Mar, 2022
- 13 locations
Masitinib in Patients With Symptomatic Mild to Moderate COVID-19
The objective of the study is to evaluate the anti-viral efficacy of 3 different dosages of masitinib in patients with symptomatic mild to moderate COVID-19.
- 0 views
- 10 Jul, 2022
- 5 locations
Therapy for Hepatitis C Virus (HCV) in Primary Treatment Failure in Pakistan
This trial is linked to a largescale observational study determining the efficacy of sofosbuvir/daclatasvir in people in Pakistan (involving a separate protocol). The observational study will identify a cohort of patients who have not responded to first-line antiviral therapy (sofosbuvir plus daclatasvir) and the optimal treatment for these patients is …
- 0 views
- 19 Oct, 2022
- 1 location
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
The purpose of this study is to see if giving reduced intensity chemotherapy, haploidentical bone marrow, post-transplant cyclophosphamide and shortened duration tacrolimus is safe and feasible for patients with very high-risk solid tumors.
- 100 views
- 04 Oct, 2022
- 4 locations
Long Term Follow up of Chronic HCV Patients Receiving DAAS
Follow up of Chronic hepatitis C Patients with moderate to severe fibrosis and cirrhosis treated with Direct Acting Antivirals after Sustained Virological Response for 4-5 years to detect changes in hepatic fibrosis and liver functions.
- 0 views
- 07 Jul, 2022
- 1 location
The Treatment in Pregnancy for Hepatitis C ("TiP-HepC") Registry (TiP-HepC)
Clinical interventions to reduce the risk of vertical transmission of hepatitis C virus (HCV) infection from mother to infant are highly limited. Direct-acting antiviral (DAA) medications have demonstrated excellent safety and efficacy in non-pregnant individuals, but there is a lack of data regarding the safety of these medications in pregnant …
- 0 views
- 30 May, 2022
- 1 location